Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$7.76 USD
+0.11 (1.44%)
Updated Jul 16, 2024 03:44 PM ET
After-Market: $7.74 -0.02 (-0.26%) 7:08 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Actinium Pharmaceuticals, Inc. [ATNM]
Reports for Purchase
Showing records 41 - 60 ( 94 total )
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actimab-A Continues to Impress at ASH as Combo Studies Expand
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
SIERRA Profile Shows Strong Ongoing Durability with Iomab-B; Top-Line Data Mid-22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
SITC Highlights Efficacy of ARC Therapy in Solid and Liquid Tumors; 3Q21 Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
SIERRA Fully Enrolled, Endgame Set for Mid-''22; Next Data Update Expected at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q21 Results; Pivotal SIERRA Data in 1H22; More Actimab Data This Year; Target Adjusted to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
2020 Results; All About SIERRA; Target Adjusted to $57
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actinium''s Approach Gets Impressive Nod; SIERRA Phase 3 Data Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Astellas Broadens its Investment into Actinium''s AWE Platform; SIERRA Data Mid-2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
SIERRA Endgame Now Set; We See Blue Skies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actimab-A Visibility Continues to Increase as We Await SIERRA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actimab-A + CLAG-M Impresses at ASH as SIERRA Awaits its Pivotal Moment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
KOL Assessments Provide a Sneak Peak of What''s to Come at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Not an Abstract Placeholder Here; Actimab-A+CLAG ASH Abstract Impresses
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q20 Results; Things About to Get Real Exciting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Iomab-ACT Combination With CAR-Ts Makes Sense; A Closer Look While Waiting for SIERRA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Following the Paths That Make Sense; NIH Links up Actinium With MSKCC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pipeline Visibility Increasing as We Await SIERRA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Critical Time Approaching Quickly; SIERRA Ad Hoc Exercised; PT Adjusted to $65 Post Reverse Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J